Comparison
Three peptides processed from the same proglucagon precursor by intestinal L-cells, yet they act on different receptors, in different tissues, producing entirely different physiological outcomes.
Quick Answer
GLP-1 acts on a broadly expressed receptor (GLP-1R) in pancreas, hypothalamus, heart, and gut, producing metabolic effects, appetite suppression, and weight loss. GLP-2 acts on a gut-restricted receptor (GLP-2R), producing intestinal mucosal growth and repair with no weight-loss effect. GLP-3 remains the least-characterised of the three, with no confirmed receptor and no clinical drug candidates as of 2025–2026. Receptor location is the pharmacological destiny.
| Attribute | GLP-1 | GLP-2 | GLP-3 |
|---|---|---|---|
| Full name | Glucagon-like peptide-1 | Glucagon-like peptide-2 | Glucagon-like peptide-3 |
| Precursor / origin | Proglucagon (GCG gene), intestinal L-cells | Proglucagon (GCG gene), same L-cells, co-secreted with GLP-1 | Proglucagon C-terminal region; secretory cell not fully characterised |
| Native half-life | ~2 minutes (DPP-4 cleavage) | ~7 minutes (DPP-4 cleavage) | Not well characterised |
| Receptor | GLP-1R (class B GPCR) | GLP-2R (class B GPCR) | Not yet confirmed |
| Primary tissue expression | Pancreas, hypothalamus, brainstem, heart, kidney, vasculature, gut | Intestinal epithelium, subepithelial myofibroblasts, enteric neurons | Unknown; limited preclinical data |
| Main physiological effect | Glucose-dependent insulin secretion; glucagon suppression; gastric emptying delay; central satiety | Intestinal mucosal growth; epithelial repair; barrier integrity; nutrient absorption | Possibly glucose regulation; largely unknown |
| Weight loss effect | Yes, central hypothalamic mechanism | No, GLP-2R absent from appetite circuits | No evidence |
| Approved drugs | Semaglutide, liraglutide, tirzepatide (dual), retatrutide (investigational triple) | Teduglutide (Gattex / Revestive), short bowel syndrome | None |
| Research maturity | Extensive: multiple Phase 3 trials, long-term CV outcome data | Moderate: one approved indication, active intestinal research | Preclinical only; receptor not confirmed |
All three GLP peptides derive from proglucagon, a 160-amino-acid precursor encoded by the GCG gene. In intestinal L-cells and brainstem neurons, prohormone convertase 1/3 (PC1/3) cleaves proglucagon into GLP-1, GLP-2, glicentin, and oxyntomodulin. In pancreatic alpha cells, a different enzyme (PC2) cleaves the same precursor to produce glucagon instead. The GLP peptides are therefore specifically intestinal and neural products, not pancreatic.
GLP-1 and GLP-2 are co-secreted from the same L-cell at the same time in response to the same nutrient stimulus. Despite this identical secretory origin, they act on structurally distinct receptors in largely non-overlapping tissue distributions, producing entirely different physiological outcomes. This is a recurring lesson in peptide biology: shared precursor does not imply shared receptor, shared tissue, or shared function.
GLP-1R is a class B G protein-coupled receptor expressed broadly across metabolically relevant tissues: pancreatic beta and alpha cells, hypothalamic appetite-regulating nuclei (arcuate, paraventricular), the nucleus of the solitary tract in the brainstem, vagal afferent terminals, cardiac myocytes, vascular endothelium, and renal tubular epithelium. This wide expression pattern explains why GLP-1 agonists simultaneously affect blood glucose, appetite, gastric motility, body weight, and cardiovascular outcomes.
GLP-2R, by contrast, is concentrated in the intestinal epithelium, subepithelial myofibroblasts, and enteric neurons. Limited extraintestinal expression exists in the brain and pancreas, but at substantially lower levels. This distribution explains precisely why GLP-2 agonists repair the intestinal mucosa without causing weight loss or metabolic effects: the receptor is simply not expressed in the circuits that produce those outcomes. GLP-2 is not a weaker GLP-1, it is a different receptor system entirely.
GLP-3R biology remains unconfirmed. Pharmacological evidence suggests binding activity distinct from GLP-1R and GLP-2R, but receptor cloning and tissue expression mapping at the level completed for GLP-1R and GLP-2R has not been published as of 2025–2026.
GLP-1R agonism activates the Gs protein, elevates cAMP, and activates PKA. In pancreatic beta cells, this triggers glucose-dependent insulin exocytosis, glucose-dependence is the key safety feature, as the mechanism requires prior glucose-driven membrane depolarisation, meaning GLP-1 agonists cannot force insulin release without adequate blood glucose. In alpha cells, GLP-1R agonism suppresses inappropriate glucagon secretion, reducing hepatic glucose output. In the enteric nervous system and vagal afferents, it slows gastric emptying, blunting postprandial glucose excursions. In the hypothalamus, it inhibits hunger-promoting NPY/AgRP neurons and activates satiety-signalling POMC/CART neurons, producing durable appetite suppression and weight loss.
GLP-2R activation via Gs–cAMP signalling in intestinal epithelial cells and subepithelial myofibroblasts drives enterocyte proliferation, reduces apoptosis, and produces a net increase in villus height and mucosal surface area. Additional effects include enhanced nutrient absorption capacity, improved intestinal barrier integrity, and increased mucosal blood flow. These actions make GLP-2 agonism the mechanism of choice for intestinal atrophy or failure, particularly short bowel syndrome. Teduglutide (Gattex / Revestive) is the clinical proof: by stimulating GLP-2R on residual bowel, it increases absorptive capacity and enables reductions in parenteral nutrition requirements. Teduglutide does not cause weight loss, consistent with GLP-2R's absence from central appetite circuits.
GLP-3 is a proglucagon-derived peptide with early preclinical data suggesting possible insulinotropic activity, but its receptor has not been sequenced, expression-mapped, or fully validated as of 2025–2026. No GLP-3 agonist has entered clinical trials. Claims about GLP-3 mechanisms should be treated with proportionate scepticism. The honest position: GLP-3's biology is interesting but incompletely characterised, and conclusions about its clinical relevance are not yet supported by the available evidence base.
GLP-1R agonists include semaglutide (Ozempic, Wegovy, mono-agonist), liraglutide (Victoza, Saxenda, mono-agonist), tirzepatide (Mounjaro, Zepbound, GLP-1R + GIPR dual agonist), and retatrutide (GLP-1R + GIPR + glucagon receptor triple agonist, investigational). All act through Gs–cAMP–PKA; differences in clinical profile reflect additional receptor targets, half-life, and structure.
GLP-2R agonists are represented by teduglutide (Gattex / Revestive), a DPP-4-resistant GLP-2 analogue approved for short bowel syndrome in adults and paediatric patients. No other GLP-2R agonist is currently approved. GLP-3R agonists: none exist as of 2025–2026, with receptor characterisation still incomplete.
The GLP family illustrates a principle that recurs throughout peptide pharmacology: sharing a precursor does not predict shared receptor biology, tissue distribution, or clinical outcome. GLP-1 and GLP-2 are co-secreted from the same cell type in the same location at the same moment, yet one produces profound systemic metabolic and appetite effects while the other acts almost exclusively on intestinal structure.
GLP-1 receptor agonists produce weight loss because GLP-1R is expressed in the hypothalamic arcuate nucleus. GLP-2 agonists do not produce weight loss not because GLP-2 lacks potency, but because GLP-2R is not expressed in appetite circuits. The receptor distribution is the pharmacological destiny. For researchers evaluating compounds in this family: metabolic and appetite outcomes belong to GLP-1R pharmacology; intestinal structural outcomes belong to GLP-2R pharmacology. Adding GLP-2R agonism to a drug candidate would be expected to add intestinal effects, not enhance weight loss or glycaemic control.
GLP-1 and GLP-2 are both proglucagon-derived peptides co-secreted from intestinal L-cells, but they act on different receptors (GLP-1R vs GLP-2R) in different tissues with different outcomes. GLP-1 targets a broadly expressed receptor and produces metabolic effects, insulin secretion, glucagon suppression, gastric emptying delay, and appetite suppression leading to weight loss. GLP-2 targets a gut-restricted receptor and produces intestinal mucosal growth, epithelial repair, and barrier integrity, with no metabolic or weight-loss effect. They share a precursor and a secretory cell, but are pharmacologically distinct systems.
No. GLP-3 is a structurally distinct peptide processed from the C-terminal region of proglucagon, different from GLP-1 in both amino acid sequence and receptor target. GLP-1 acts on the well-characterised GLP-1 receptor; GLP-3's receptor has not been confirmed at the same level. Despite sharing the proglucagon precursor, they are separate molecules with separate (presumed) receptors. GLP-3 should not be conflated with GLP-1 or used as a substitute term for it.
The primary approved GLP-2 receptor agonist is teduglutide (Gattex in the US, Revestive in Europe). It is a DPP-4-resistant GLP-2 analogue approved for short bowel syndrome in adults and paediatric patients. In SBS, teduglutide increases absorptive capacity of the residual intestinal mucosa, enabling reduction in parenteral nutrition volume. No other GLP-2R agonist is currently approved or in late-stage clinical trials as of 2025–2026.
There is no clinical evidence that GLP-3 causes weight loss. Weight loss from GLP-1 receptor agonists occurs because GLP-1R is expressed in hypothalamic appetite-regulating circuits. GLP-3's receptor has not been confirmed, and there is no evidence of expression in those circuits. No GLP-3 agonist has demonstrated weight loss in clinical trials, partly because no such compound has reached clinical trials as of 2025–2026.
The difference is due entirely to receptor tissue distribution. GLP-1R is expressed in the hypothalamic arcuate nucleus, where agonism inhibits NPY/AgRP hunger-promoting neurons and activates POMC/CART satiety neurons, reducing caloric intake and producing weight loss. GLP-2R is concentrated in intestinal epithelium and enteric neurons, not in appetite-regulating brain regions. A GLP-2 agonist stimulating GLP-2R in the gut cannot produce central appetite suppression because the receptor is not present in those circuits. The tissue where a receptor is expressed determines what a drug targeting that receptor can do.
Related Comparisons